Chronic Lymphocytic Leukemia | Specialty

Triggers to Initiate Therapy for Follicular Lymphoma

August 15th 2017

Risk Stratifying Patients With Follicular Lymphoma

August 15th 2017

Follicular Lymphoma: Diagnosis and Staging

August 15th 2017

Dr. Furman on Considering Factors for Upfront Therapy in CLL

August 15th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).

Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLL

August 14th 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.

Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

August 10th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Dr. Byrd on Updated RESONATE Findings in CLL

August 10th 2017

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of Medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the updated findings of the RESONATE trial in chronic lymphocytic leukemia (CLL).

SF3B1 Mutation Associated With Poor Survival in CLL

August 8th 2017

Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.

Dr. Furman on Second-Generation BTK Inhibitors in CLL

August 3rd 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).

Dr. Chavez on Ongoing Efficacy and Challenges With Ibrutinib in CLL

August 1st 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the ongoing efficacy but also challenges with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).

CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL

July 31st 2017

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Combos Explored to Enhance CLL Outcomes

July 28th 2017

Julio Chavez, MD, discusses the current state of CLL and emerging regimens moving through the pipeline.

Predictive Factors Found for Treatment With FCO in CLL

July 14th 2017

A mutation on the NOTCH1 gene was shown to be an independent predictive factor for the reduced efficacy of ofatumumab (Arzerra), a human monoclonal CD20 antibody, in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Obinutuzumab and Bendamustine Combo Shows Encouraging Activity in Upfront CLL

July 14th 2017

The anti-CD20 monoclonal antibody obinutuzumab (Gazyva) combined with bendamustine (Treanda; BG) in the frontline setting for patients with chronic lymphocytic leukemia was found to induce high rates of complete response and minimal residual disease negativity with no unexpected safety signals, according to results from a phase II open-label, multicenter study.

Ibrutinib-containing Combination Induced High Rate of Bone Marrow MRD Negativity, 100% ORR in IGHV-Mutated CLL

July 12th 2017

Patients with IGHV-mutated chronic lymphocytic leukemia had high rates of minimal residual disease-negative status in bone marrow following first-line treatment with a combination of ibrutinib (Imbruvica), fludarabine, cyclophosphamide, and obinutuzumab.

Analysis Shows Response to Ibrutinib in CLL Patients With 11q Deletion

July 11th 2017

Thomas Kipps, MD, PhD, discusses the details of the integrated analysis from the iwCLL meeting, his ongoing research with ROR1 as a target in chronic lymphocytic leukemia, and pivotal combination studies being conducted with ibrutinib.

Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma

June 28th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

Ibrutinib/Venetoclax Yields Dramatic Blood Response in Patients With Relapsed/Refractory CLL

June 26th 2017

Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

June 24th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

FDA Approves Subcutaneous Rituximab for Blood Cancers

June 22nd 2017

The FDA has approved subcutaneous rituximab (Rituxan Hycela) for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia.